Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 94Leukemia, Lymphocytic, Chronic, B-Cell 56Neoplasms 37Recurrence 28Lymphoma, Non-Hodgkin 25Myelodysplastic Syndromes 21Multiple Myeloma 18Leukemia 16Lymphoma, Large B-Cell, Diffuse 11Leukemia, Myelomonocytic, Chronic 10Hematologic Neoplasms 10Lymphoma, Mantle-Cell 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Lymphoma, B-Cell, Marginal Zone 6Leukemia, Myeloid 6Lymphoma 5Chromosome 17 deletion 5Lymphoma, B-Cell 4Breast Neoplasms 4Waldenstrom Macroglobulinemia 3Small Cell Lung Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Neuroblastoma 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Lymphoproliferative Disorders 2Hematologic Diseases 2GATA2 Deficiency 2

Interventions

venetoclax 1quizartinib 1Daunorubicin 1Cytarabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Sarcoma, Myeloid × venetoclax × Clear all
NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡